-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Small cell lung cancer (SCLC), which accounts for about 15% of lung cancers, is a highly malignant and almost fatal disease
In the new study, researchers at Washington University in St.
In previous work, the scientists found that a protein called RNF113A is associated with the ability of cancer cells to repair alkylated damage, a pattern
With this new goal in mind, the scientists investigated whether blocking SMYD3 could improve the effectiveness of
To investigate the effects of SMYD3 in SCLC, the researchers expanded their observations to patient-derived tumor xenografts and mouse models
Because cyclophosphamide has stronger side effects than platinum-based chemotherapy drugs, cyclophosphamide has somehow fallen out of favor in recent decades, but new research may mean it deserves to be revisited
Interestingly, we found that SMYD3 and RNF113A both have similar expressions between the four scLC subtypes recently characterized
Nima Mosammaparast, co-first author of the study, said: "We are in discussions with a number of other groups to start Phase I clinical trials
Original source:
Lukinović V, Hausmann S, Roth GS, Oyeniran C, Ahmad T, Tsao N, Brickner JR, Casanova AG, Chuffart F, Benitez AM, Vayr J, Rodell R, Tardif M, Jansen PWTC, Couté Y, Vermeulen M, Hainaut P, Mazur PK,Mosammaparast N, Reynoird N.
PDF file download: Click to open
